In murine solid tumor models, including ovarian cancer, glioblastoma, and pancreatic cancer, the CXCR4 antagonist AMD3100 has been shown to decrease tumor angiogenesis (5, 15) and revascularization (16), reduce lung metastasis (17, 18), and induce infiltration of CD8+ T cells into tumors (15, 19). This evidence concerns the gene CXCR4 and neoplasm.